Pulse Biosciences Q2 net loss widens, cash position strengthens
PLSE•Key cost and revenue drivers
- Clinical program investment — Increased costs were driven by expanded clinical trial activity and compensation expenses.
- Controlled commercial launch — The company recorded sequential revenue growth during the controlled launch while focusing on market development.
- Limited customer base — Pulse Biosciences said it remained focused on procedural utilization within a limited customer base based on clinical results.
Quarterly results and cash position
Pulse Biosciences said its Q2 2026 revenue grew sequentially during a controlled commercial launch, while GAAP net loss widened year over year due to higher clinical and compensation expenses.
The company also raised $46.8 million in net proceeds through its ATM program, strengthening its cash position.
Selected financial and analyst details
| Metric | Actual |
|---|---|
| Q2 Net Loss | $24.66 million |
| Q2 Income from Operations | -$25.27 million |
The current average analyst rating on the shares is buy, with 3 strong buy or recommendations, no , and no or . The average consensus recommendation for the advanced medical equipment & technology peer group is .
